Modulation of humoral immune response to oral BCG vaccination by Mycobacterium bovis BCG Moreau Rio de Janeiro (RDJ) in healthy adults

dc.creatorMaia, Renata Monteiro
dc.creatorSampaio, Maria B. Ortigão de
dc.creatorPinho, Rosa T.
dc.creatorCastello Branco, Luiz R. R.
dc.date2020-01-23T13:03:09Z
dc.date2020-01-23T13:03:09Z
dc.date2006
dc.date.accessioned2023-09-26T20:48:33Z
dc.date.available2023-09-26T20:48:33Z
dc.identifierMAIA, Renata Monteiro et al. Modulation of humoral immune response to oral BCG vaccination by Mycobacterium bovis BCG Moreau Rio de Janeiro (RDJ) in healthy adults. Journal of Immune Based Therapies and Vaccines. v. 4, n. 4, p. 1-6, 2006.
dc.identifier1476-8518
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/39455
dc.identifier10.1186/1476-8518-4-4
dc.identifier1476-8518
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8864271
dc.descriptionBackground: Oral administration of BCG was the route initially used by Calmette and Guérin, but was replaced by intradermal administration in virtually all countries after the Lubeck accident. However, Brazil continued to administer oral BCG Moreau RDJ, which was maintained until the mid-1970s when it was substituted by the intradermal route. Although BCG vaccination has been used in humans since 1921, little is known of the induced immune response. The aim of this study was to analyse immunological responses after oral vaccination with M. bovis BCG Moreau RDJ. Methods: This study in healthy volunteers has measured cellular and humoral aspects of the immunological response to oral M. bovis BCG Moreau RDJ in Rio de Janeiro, Brazil. T-cell trafficking and Th1 and Th2 cytokine responses are described, as well as isotype-specific antibody production using novel techniques. Results: Oral immunisation has no adverse effects. We have shown that there are cellular and humoral immunological responses after oral immunisation. Oral revaccination does not induce a positive skin test in responsive individuals and multiple booster orally was able to induce modulation in humoral immunological responses (switch from IgG to IgA) in previously immunised subjects and incapable of inducing tolerance. In contrast, the cellular immune response does not differ between vaccinated individuals with positive and negative skin test reactions. Conclusion: All subjects, including those who did not respond to the skin test at study commencement, were capable of mounting humoral and cellular immune response to the antigens tested.
dc.formatapplication/pdf
dc.languageeng
dc.publisherBioMed Central
dc.rightsopen access
dc.subjectResposta imune humoral
dc.subjectVacinação oral ao BCG
dc.subjectMycobacterium bovis BCG Moreau
dc.subjectAdultos saudáveis
dc.subjectRio de Janeiro
dc.subjectHumoral immune response
dc.subjectOral BCG vaccination
dc.subjectMycobacterium bovis BCG Moreau
dc.subjectRio de Janeiro
dc.subjectHealthy adults
dc.titleModulation of humoral immune response to oral BCG vaccination by Mycobacterium bovis BCG Moreau Rio de Janeiro (RDJ) in healthy adults
dc.typeArticle


Este ítem pertenece a la siguiente institución